Literature DB >> 9588308

Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression.

B A Daniels1, K C Kirkby, D A Hay, B J Mowry, I H Jones.   

Abstract

OBJECTIVE: The aim of this study was to examine the rate of rehospitalisation for schizophrenia, bipolar disorder and depression over a 5-year period in Tasmania, and to identify predictors of the number and duration of readmissions.
METHOD: The Tasmanian Mental Health Register was used to study the 5-year pattern of rehospitalisation for all patients admitted to a Tasmanian public psychiatric inpatient facility with a primary diagnosis of schizophrenia, bipolar disorder or depression, in 1983 or 1984.
RESULTS: Seventy-one percent of patients receiving a diagnosis of schizophrenia were readmitted in the 5-year period, compared to 59% for bipolar disorder and 48% for depression. For all three diagnoses, the number of prior admissions was a predictor of the number of readmissions and the total number of days spent in hospital in the follow-up period. Age and sex also had significant effects, which varied across diagnostic groups.
CONCLUSIONS: A substantial proportion of patients hospitalised for schizophrenia, bipolar disorder or schizophrenia were rehospitalised during the next 5 years. Patients with more previous admissions had more readmissions than those with fewer previous admissions.

Entities:  

Mesh:

Year:  1998        PMID: 9588308     DOI: 10.3109/00048679809062740

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  5 in total

1.  Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.

Authors:  Todd S Woodward; Kwanghee Jung; Geoffrey N Smith; Heungsun Hwang; Alasdair M Barr; Ric M Procyshyn; Sean W Flynn; Mark van der Gaag; William G Honer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-15       Impact factor: 5.270

2.  Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

Authors:  Florian Seemüller; Sebastian Meier; Michael Obermeier; Richard Musil; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03-04       Impact factor: 5.270

Review 3.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 4.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

5.  The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective.

Authors:  Jan Zeidler; Lara Slawik; Jochen Fleischmann; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2012-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.